Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.

Benelli R, Barboro P, Costa D, Astigiano S, Barbieri O, Capaia M, Poggi A, Ferrari N.

Int J Mol Sci. 2019 Dec 3;20(23). pii: E6091. doi: 10.3390/ijms20236091.

2.

Human Gut-Associated Natural Killer Cells in Health and Disease.

Poggi A, Benelli R, Venè R, Costa D, Ferrari N, Tosetti F, Zocchi MR.

Front Immunol. 2019 May 3;10:961. doi: 10.3389/fimmu.2019.00961. eCollection 2019. Review.

3.

A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.

Capaia M, Granata I, Guarracino M, Petretto A, Inglese E, Cattrini C, Ferrari N, Boccardo F, Barboro P.

Int J Mol Sci. 2018 Jun 30;19(7). pii: E1920. doi: 10.3390/ijms19071920.

4.

Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells.

Tosetti F, Venè R, Camodeca C, Nuti E, Rossello A, D'Arrigo C, Galante D, Ferrari N, Poggi A, Zocchi MR.

Oncoimmunology. 2018 Jan 19;7(5):e1421889. doi: 10.1080/2162402X.2017.1421889. eCollection 2018.

5.

Prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2), a complex target for colorectal cancer prevention and therapy.

Benelli R, Venè R, Ferrari N.

Transl Res. 2018 Jun;196:42-61. doi: 10.1016/j.trsl.2018.01.003. Epub 2018 Feb 2. Review.

PMID:
29421522
6.

Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.

Ferrari N, Granata I, Capaia M, Piccirillo M, Guarracino MR, Venè R, Brizzolara A, Petretto A, Inglese E, Morini M, Astigiano S, Amaro AA, Boccardo F, Balbi C, Barboro P.

Cell Commun Signal. 2017 Dec 8;15(1):51. doi: 10.1186/s12964-017-0206-x.

7.

The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.

Brizzolara A, Benelli R, Venè R, Barboro P, Poggi A, Tosetti F, Ferrari N.

Cancer Lett. 2017 Aug 1;400:9-17. doi: 10.1016/j.canlet.2017.04.025. Epub 2017 Apr 25.

PMID:
28450158
8.

Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity.

Zocchi MR, Costa D, Venè R, Tosetti F, Ferrari N, Minghelli S, Benelli R, Scabini S, Romairone E, Catellani S, Profumo A, Poggi A.

Oncoimmunology. 2017 Jan 6;6(3):e1278099. doi: 10.1080/2162402X.2016.1278099. eCollection 2017.

9.

Celecoxib increases EGF signaling in colon tumor associated fibroblasts, modulating EGFR expression and degradation.

Venè R, Tosetti F, Minghelli S, Poggi A, Ferrari N, Benelli R.

Oncotarget. 2015 May 20;6(14):12310-25.

10.

Expression of nuclear matrix proteins binding matrix attachment regions in prostate cancer. PARP-1: New player in tumor progression.

Barboro P, Ferrari N, Capaia M, Petretto A, Salvi S, Boccardo S, Balbi C.

Int J Cancer. 2015 Oct 1;137(7):1574-86. doi: 10.1002/ijc.29531. Epub 2015 Apr 6.

11.

Glycogen synthase kinase 3 regulates cell death and survival signaling in tumor cells under redox stress.

Venè R, Cardinali B, Arena G, Ferrari N, Benelli R, Minghelli S, Poggi A, Noonan DM, Albini A, Tosetti F.

Neoplasia. 2014 Sep;16(9):710-22. doi: 10.1016/j.neo.2014.07.012.

12.

Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progression.

Barboro P, Ferrari N, Balbi C.

Cancer Lett. 2014 Oct 1;352(2):152-9. doi: 10.1016/j.canlet.2014.06.019. Epub 2014 Jul 10. Review.

PMID:
25016060
13.

Prostate cancer: prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression.

Barboro P, Salvi S, Rubagotti A, Boccardo S, Spina B, Truini M, Carmignani G, Introini C, Ferrari N, Boccardo F, Balbi C.

Int J Oncol. 2014 May;44(5):1589-98. doi: 10.3892/ijo.2014.2345. Epub 2014 Mar 14.

PMID:
24626777
14.

Androgen receptor activity is affected by both nuclear matrix localization and the phosphorylation status of the heterogeneous nuclear ribonucleoprotein K in anti-androgen-treated LNCaP cells.

Barboro P, Borzì L, Repaci E, Ferrari N, Balbi C.

PLoS One. 2013 Nov 13;8(11):e79212. doi: 10.1371/journal.pone.0079212. eCollection 2013.

15.

The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.

Laurent S, Queirolo P, Boero S, Salvi S, Piccioli P, Boccardo S, Minghelli S, Morabito A, Fontana V, Pietra G, Carrega P, Ferrari N, Tosetti F, Chang LJ, Mingari MC, Ferlazzo G, Poggi A, Pistillo MP.

J Transl Med. 2013 May 1;11:108. doi: 10.1186/1479-5876-11-108.

16.

Impact of CXCL1 overexpression on growth and invasion of prostate cancer cell.

Benelli R, Stigliani S, Minghelli S, Carlone S, Ferrari N.

Prostate. 2013 Jun;73(9):941-51. doi: 10.1002/pros.22640. Epub 2013 Jan 17.

PMID:
23334998
17.

Celecoxib induces proliferation and Amphiregulin production in colon subepithelial myofibroblasts, activating erk1-2 signaling in synergy with EGFR.

Benelli R, Venè R, Minghelli S, Carlone S, Gatteschi B, Ferrari N.

Cancer Lett. 2013 Jan 1;328(1):73-82. doi: 10.1016/j.canlet.2012.09.008. Epub 2012 Sep 23.

PMID:
23010081
18.

Xanthohumol impairs human prostate cancer cell growth and invasion and diminishes the incidence and progression of advanced tumors in TRAMP mice.

Venè R, Benelli R, Minghelli S, Astigiano S, Tosetti F, Ferrari N.

Mol Med. 2012 Dec 6;18:1292-302. doi: 10.2119/molmed.2012.00174.

19.

The AKT/NF-κB inhibitor xanthohumol is a potent anti-lymphocytic leukemia drug overcoming chemoresistance and cell infiltration.

Benelli R, Venè R, Ciarlo M, Carlone S, Barbieri O, Ferrari N.

Biochem Pharmacol. 2012 Jun 15;83(12):1634-42. doi: 10.1016/j.bcp.2012.03.006. Epub 2012 Mar 17.

PMID:
22445931
20.

Effects of polyphenol extract from olive pomace on anoxia-induced endothelial dysfunction.

Palmieri D, Aliakbarian B, Casazza AA, Ferrari N, Spinella G, Pane B, Cafueri G, Perego P, Palombo D.

Microvasc Res. 2012 May;83(3):281-9. doi: 10.1016/j.mvr.2012.02.010. Epub 2012 Feb 23.

PMID:
22386654

Supplemental Content

Loading ...
Support Center